Why I love Antimicrobial Stewardship in Primary Care

Nest week, on the 18th November, it's European Antibiotic Awareness Day. As part of our activities for this event, we've been supporting the Listen To Your Gut campaign (www.listentoyourgut.org.uk). This is aimed primarily at parents, helping them understand the role bacteria have in keeping us healthy, and understanding why we want to try to look after our 'healthy bugs' by only giving antibiotics when they're really necessary. The 'Treating Your Infection' self-help guide that goes along with this teaches people what to expect from self-limiting infection, and symptoms to look out for that suggest they need to see a doctor. Yesterday I launched this programme to GPs in North Devon at their prescribing day, and today I went to a practice to talk in more detail about antibiotic stewardship. This is by far the most enjoyable bit of my my job, and here are some thoughts as to why that's the case.

1. Data. It's so easy to get data on things in primary care, in ways that are completely impossible often in secondary care. Prescriber, time of prescription, nature of consultation (face to face vs telephone), basic patient demographics, co-morbidities. The one thing that's a bit hard is indication for antibiotics, but that's often not that important if you approach the data in the right way - this is just a starting point for conversation. So we see some interesting things coming out that are the starting points for challenging (and often supporting) practice. So for instance,

- 20% of young people (aged 20-39) get an antibiotic each year. This is mainly amoxicillin. And it's mainly for coughs and colds.

- 10% of antibiotic prescriptions occur within 2 weeks of a previous prescription. Why is this? Is it treatment failure? Intolerance to first choice? Never infection in the first place? If someone is not better in 3 days in primary care, how often is there an indication for a second course? I don't know the answer to this - but I'd quite like to think about it a bit more. Do any microbiologists understand this group of patients?

- If you get given fluclox, then the follow on antibiotics are doxycycline, co-amoxiclav and clarithromycin. What could these antibiotics be doing that fluclox wasn't doing? Is it a dosing issue? Is it non-infective? Is it pilonidal sinuses involving gram negatives? And how actually do you manage these nowadays in primary care, especially now that access to surgical specialities is apparently more difficult?

Nursing prescribers are the biggest prescribers by far. They see all the minor ailments. Are we giving them the support they need?

2. Trusted relationships and continuity of care. GPs really know their patients and their lives. They work in close knit teams and have a shared purpose. And, having worked closely with them for a number of years, it feels that I have developed a culture of trust with them. We can talk about anything without fear of judgement. They can talk with me about specific issues in context, not abstract 'guideline' derived approaches which often fail to address the difficult situations which do not 'fit' our medical archetypes. It's no good saying "Don't ever give prophylaxis for urinary tract infections" if you haven't sat with them and talked in a specific way about just what you would do, and show that you understand the problem from the perspective of the patient. I gained 'validity' here by doing joint clinics with GPs talking to patients with recurrent infection.

We had a great discussion today about different techniques GPs use to talk to patients. Again, this sort of peer led discussion is a key part of any 'norming' part of a behaviour change methodology, and can only be done within a culture of trust. We talked about how it's really helpful to draw a graph of 'symptoms' vs 'time' and show patients where they are on the line. We then thought about how the 'Listen To Your Gut' message could fit in after this. Then talk about red flag symptoms and whether the patient has any. And then really allow the decision to prescribe antibiotics to sit with the informed patient. It's no longer a battle, but a conversation.

3. The detail is important. So developing this concept of validity, you have to be able to talk in detail about things in a way that connects with those asking the question. If you can't have a trusted opinion on how to manage a patient who's had a cough for 3 weeks (even if it's "I don't know - there is no evidence; my feeling is that this is appropriate") then there is not a huge point in having a meeting.

4. It's a two way thing. These meetings in primary care are not about me ("the expert") giving information. It's partly about this ("frankly I only really worry when they're rigoring and dropping their blood pressure...you can probably watch and wait in most other situation"; "co-amoxiclav adds no significant additional cover to fluclox for skin infection and has worse pharmacokinetics and more side effects" "I know we use multiple antibiotics to treat TB to stop emergence of resistance. But it doesn't seem to work that way in most infection, and you just increase side effects.")

But for me, it's more about giving me a sense of the demand as it present to primary care, and thinking about how we help.  Just what do you do in a confused old person? In hospital they get chest X-rays, blood tests by the gallon and we then sort of have a plan. This is just so much harder in primary care. How can we support people to do this better. Urgent bloods? In someone with otitis media not responding to amoxicillin, is it reasonable to give co-amox? I have to confess I don't have a strong opinion on this - I can explain the bacteriology of why this might be appropriate because of resistant Haemophilus - but actually, do I know what the natural history of this disease is, and what investigations are appropriate, if any? If we don't hear these stories as they present, how can we have an opinion?

Three next steps for primary care infection optimisation

1. Is stewardship a bit too negative? Our common purpose is to optimise the care of the patient in front of us with possible infection. I would suggest that we should talk more in this positive manner. Again, I would note how the Listen To Your Gut message fits well with this approach.

2. We need to develop antimicrobial stewardship teams that work across health communities. It is important I know about how infection is managed in both primary and secondary care. We need to develop teams that can work in this way.

3. We need to work with all stakeholders - and we clearly need much more focus on non-medical prescribers; but also HCAs and nursing homes. They may not be able to prescribe, but they can strongly influence prescriber behaviour by the way they relate the patient story or request investigations.

Antibiotic sensitivity testing - are current methods leading to bad stewardship?

We did an interesting exercise in the lab today trying to quantify the degree of 'uncertainty' in a lab report. We did what many people already do for internal quality assurance and just put 20 urine specimens through the lab independently. We looked at culture report, sensitivity report, pyuria report, and whether 'extra' tests were done. It was good to see surprisingly high levels of certainty, even in things I thougeh might be a bit subjective, such as assessment of level of pyuria.

The uncertainty around sensitivity testing however made me revisit some basic assumptions. We are looking for a zone of inhibition around an antibiotic impregnated disc. If that zone falls below a certain size we say the organism is resistant to that antibiotic. This cut off, or breakpoint, is defined by committee and is based on a combination of pharmacokinetic and epidemiological criteria. When you consider the science behind the technique, we are making big calls based on small interpretative differences. And this matters - clinicians will, quite rightly, not use an antibiotic that has been called resistant by the lab. So if we call an antibiotic resistant we are denying it to the patient. For urinary tract infections we only have about five oral antibiotics we can routinely use. If we lose some of these we cut down our options - we see increasing number of patients with no oral options left - these patients are often admitted to hospital for intra venous therapy. Perhaps worse still, we push clinicians towards using 'last resort' antibiotics, such as meropenem. Each meropenem prescription brings the day of antibiotic Armageddon ever closer, when we have no good options left.

So what happened when we looked at uncertainty of antibiotic resistance testing? Small numbers, but we saw 3 out of about 48 zones were reported discrepantly. ie. One lab scientist called resistant, the other called sensitive. When we looked at why this was, all the zones were on the breakpoint - it would have been easy to read either way. So there are some people who will respond to this by saying things like "standardise better, and get some calibrated measuring calipers, or an ISO accredited ruler, and beat your scientists harder."

But in response to that, is worth viewing the EUCAST website. They've got loads of data on zone sizes.  We can see a few things :

1. If we look at the distribution of zone sizes in bacteria we often see a normal distribution, with a separate population of resistant organisms with very small zone sizes. But the (somewhat arbitrary) breakpoint often sits at one end of the normal distribution, so including many sensitive organisms.
2. If we look at the distribution of zone sizes in organisms that are known to be resistant, they generally have very small zone sizes (with some notable exceptions)
3. If we look at the inherent variability of zone sizes measurement, by putting the same organism though the same process every day (what we do for internal quality control) we see generally about a 5-10mm variation. That's about 20% expected variation in zone sizes. And we make calls based on less than 5% differences - is this really a good idea, or even scientifically correct?

So this is my current thinking. Breakpoints are useful for epidemiological information and studying trends over time. But they are perhaps massively unhelpful in clinical practice in many situations. I wonder whether we should report 'sensitive' if a big zone, 'resistant' if no/very small zone, and call everything else intermediate/uncertain. But looking at the data, chances are most people will respond just fine in these situations. Saving them, and us, from yet more unnecessary broad spectrum antibiotic use.

Targets, KPIs and why we should be wary

In a 2006 paper, Bevan discusses the problems with targets. In summary these are twofold. One is synedoche - the assumption that the part represents the whole. The other is gaming. Gaming leads to 3 phenomena.

The first is the ratchet effect where things get 'better' year on year, often as a result of setting future targets against benchmarks of previous performance. We see this a lot in healthcare. It is rife in infection control - 95% hand hygiene compliance rates (when the best studies achieve only about 60%) is one example. No hospital wants to look like its hand hygiene is worse than that of the next door hospital.

The second is the threshold effect, where managers alter the system to deliver to the target...and no more. There is no reward for doing better. In the paper, Bevan sites the evidence that ambulance trusts redistributed response centres to urban areas. This had little effect on urban response times, beyond bringing them below an 8 minute threshold, but had a profound effect on rural response times. But as these were relatively small numbers, the effect on the target could be ignored. 

The third type of gaming is manipulation of the output data. There are many ways to do this. Clinical coding is a minefield of variability to be exploited here. And we are all familiar with the stories of A+E trolleys becoming beds. I recently heard about an out of hours GP service that performance manages against time to triage. Very worthy. But clinicians quickly learn they can stop the clock by entering a single full stop into the clinical record, getting the managers off their backs, while they get on with doing the work they were trained to do.

But more worrying is actual distortion of clinical practice. So, for example, surgeons refusing high risk cases. And I know of one laboratory that doesn't load blood cultures if clinical details are vague in order to hit MRSA targets. There is a valid clinical argument here, but it's quite weak, and surely this decision is now open to considerable criticism in the face of the target culture.

Bevan discusses how the target culture in the USSR led initially to large productivity gains over the first couple of decades. But this was followed by stagnation and ultimate failure. Perhaps we see the same in health. Targets initially are well meaning and often focus activity on issues of concern. But quickly, the target becomes the point, and the purpose of the target as an agent of change becomes traduced.

Bevan argues that we can improve things. More random checks perhaps, using more random measures. But ultimately we probably just need more face to face peer led assessment. And for me, this probably leads us away from the comfort of the target, to a more nuanced narrative assessment written in collaboration between assessors and those doing the work.

Why clinicians shouldn't think about test costs

There is evidence that making clinicians aware of test costs reduces requesting, and this has been used as justification for including costs at the requesting stage as a means of reducing unnecessary testing. This would go into the typical arsenal of 'demand management'.

Clinicians are already under pressure to make complex management decisions that are in the best interest of the patient. How does adding more information into this equation at this stage help?

The way costs are interpreted will be dependent on how they are framed. So I could say that it costs £50 to manage a possible infection.  Adding a CRP into the mix, at about £5, is relatively trivial. Or I could say that a CRP is about 50 times more expensive than a standard biochemical test, and that this is now a considerable burden on lab expenditure.

The clinician will either then choose to do the test (it's not that expensive, it doesn't really matter) or choose not to do the test (I need to do my bit to save the health economy money). There are at least two problems with this approach.

1. It leads the clinician away from their primary purpose, which is to optimise care for the patient in front of them. They cannot be expected to make an accurate economic assessment on the basis of one piece of information.

2. True costs of testing will be hidden. So there is less pressure to reduce high volume but low cost testing. This adds up, but an individual clinician working in isolation cannot be expected to understand or evaluate this.

There must be an optimum level of testing. What we need are ways to understand the utility of diagnostics across whole pathways. We need to understand how these tests benefit (or harm) patients. We need ways of assessing the true costs of tests to the health service, with transparency of how labs price their tests, and with inclusion of downstream costs.  We then need to find ways to help clinicians order these tests accurately.

All this must include an assessment of cost effectiveness. But keep this out of the clinic and do it with proper informed debate.

I will add that this almost certainly needs new ways of working between labs and users, and needs approaches to contracting that break the insidious link between activity and income. But that's another blog.

The Kings Fund on Better Value and Pathology Optimisation

For a number of years here in North Devon we have been working towards creation of a pathology optimisation capability. This will have the remit of working across patient pathways to improve the way we use diagnostic tests, from the decision to do the test all the way through to the way that results inform management. We have borrowed heavily from the thinking and structure behind Devon's medicines optimisation team, in which pharmacists help ensure that medicines are used to maximum effect. They aim to balance costs and benefits at all levels across the health system - from individual patient prescribing situations, to prescribing policy and formulary support.

So it is exciting that tomorrow we will launch a new pathway for DVT management in primary care, which has been arrived at through close collaborative working between pathology, pharmacy, physicians and primary care. And even more excitingly, we will also introduce the new optimisation team, which consists of two of our North Devon biomedical scientists, a pathologist, a GP, a GP trainee, and a public health doctor. We have also secured funding for link GPs in all practices who will work with the optimising team to a) understand demand b) study the gaps between demand and delivery and c) work towards closing this gap.

It is sometimes a little disconcerting to be doing things that few others see as possible. Although we have heard many good things about the work we have been doing, few others seem to be trying to replicate it. So it is reassuring to read the recently released Kings Fund report "Better Value In the NHS." This document is a call to arms for clinicians to lead the way on improving value in the NHS, and sees this as the way to ensure the future sustainability of the service. Many of the things it calls for are in our Pathology Optimisation service.

1. We need to tackle overuse and underuse of services. This is optimisation. Overuse, in particular, is hugely expensive. We have seen that this is not just financial, but also through opportunity cost. And in services that are stretched, where demand exceeds capacity (and this is almost everywhere, but particularly in primary care) it is this opportunity cost that is slowly killing the sort of healthcare that people actually want. The use of diagnostics has skyrocketed over the last decade. This has been associated with negligible benefits (as we have posted previously) but considerable harms, some physical, some mental. 5% of test results lie outside reference ranges. We have seen how this leads to activity that is usually of no benefit to patients, but that sucks the lifeblood from the NHS.

2. Teams delivering better care. We cannot design services in isolation. This is a traditional problem for pathology, which produces highly accurate results, but often throws up its hands in despair when asked to consider whether the tests were actually appropriate or results acted on appropiately. "These are not things we can control." "The standard of education these days is just not what it was." But we have shown that we can act on the pre- and post - analytical pathways; and that the only way to do this is through close engagement with all stakeholders, with the purpose of the pathway, as defined by the citizen through their stories, as the compass which keeps us on track.

Our latest work, on the DVT pathway, was blocked by silo thinking. We could see no way to get an urgent D-dimer test performed in primary care. We could see no way of dealing with anticoagulation in low risk (below knee) potential DVTs if an ultrasound was not available immediately. And yet we heard the patient stories of care that did not seem to care - patients shunted around the system being treated in ways that were certainly sub-optimal at best (such as having to travel 40 miles to have a blood thinning injection that was not actually necessary).

These problems were unblocked when we got together as a team and understood the problems from others' perspectives, challenging the limits of what was possible. For our pathway, the key enablers came when the laboratory showed that a D-dimer was stable in a refrigerated citrated blood for 24 hours; and the physicians said it was safe to wait 24 hours before making a treatment decision on a low risk (below knee) DVT. We must not be complacent that we have 'got it right', and the optimisation team will be important players in embedding this pathway into practice, and monitoring its efficacy.

I will leave the last words to the Kings Fund, :

"The challenge facing the NHS over the coming years is fundamentally about improving value rather than reducing costs. Framing the debate in these terms emphasises the role of quality and outcomes in meeting the challenges facing the health system, as well as providing the right language to engage clinicians and frontline staff in making change happen."

Pathology supporting chronic disease management: It's not all about the numbers!

I like numbers and I like words and stories, and I like them both the same.

The drive to prove the good practice of medicine through numbers and targets has almost lost us the art of words and stories. We can’t measure the healing powers of words; does this mean they don’t count?

Pathology can provide us with a number. We can make sure we test for that number and ensure that we move that number to target. Here we have someone with ischaemic heart disease; they have a cholesterol of 3, that’s great! That’s well in target. But what’s the story?

The story is not the story we think, and it starts from the very outset. When we started talking to patients about their annual chronic disease reviews, we found this....

Patients are called into their GP practice to have their annual heart disease monitoring review. They are asked to make an appointment for a blood test. No-one has told them what blood tests they will have done. They have their bloods taken. ‘I had loads of bloods taken’, ‘they test for everything don’t they?’, ‘I think they even pick up cancer’

Patients aren't really sure what the blood tests are for, and they start making up their own stories....

Not knowing what the bloods are for, or what they mean, creates stories that can make their health worse; or distract them from important health issues.... ‘My cholesterol is 3, that means my fat is good doesn't it?That means I don’t need to lose any weight...’

For pathology, ensuring that a number leads to good conversations and good stories that can help patients on the path to good health is as important as generating a correct and accurate number.

Supporting patients to know what blood tests they are having. Supporting patients to understand what the blood tests are for and the meaning of the result starts the story off on the right footing. And if the story starts off on the right footing, everything downstream has a chance of success. What chance is there of supporting a patient to lose weight, when their cholesterol is so good!

Supporting users to consent patients for blood tests every time: What test? Why? What it could mean? What it does mean. Supporting users to embed this into written information at annual review- recall letters, consent and reporting.

Stories count as much as numbers.

Some thoughts on leading measures - with education as an example

Leading measures are things that tell us how we are performing, right now, against things that matter. We are not very good at measuring them. Instead we measure things like percent compliance against a protocol, or satisfaction rates, or exam pass rates. These are all lagging measures - they happen after the event and do not really tell us very much about what we can do to improve. They also don't usually tell us whether what we are doing is actually very helpful/desirable; and as a consequence of this tend to lead to 'gaming'; in which individuals or organisations tend to alter their behaviour in order to hit the target. "Hit the target, miss the point" as my mentor Andy Brogan would say.

The trouble is that the lagging measures are so engrained in all that we do in healthcare that it's very difficult to start thinking differently. So I find it helpful to think about things in which I have only a rudimentary understanding of the process, but I have quite strong views (as a citizen) of what matters. Education is one example, and so here are some thoughts on what matters, and how I might measure these as a school governor. With thanks to @Primary_Ed for the structure around growth mindsets.

1. It matters that my child enjoys school
Ask a child when they turn up for school in the morning if they are looking forward to it.

2. It matters that my child has a 'growth mindset'. 
Note I, personally, am not interested in whether my child has learned any facts - this is what Wikipedia is for. But it does matter that they know how to learn, and they know how to access facts, make sense of them, and use them to solve real problems and be interested in the world around them.

I think I would want every child to show me a balanced example of these things about their work, either in books, or in the classroom:

a. This work is OK - but is it my best work?
I know what I am going to do next to make this work better
I understand what I am doing at the moment and am now practising making sure I can do it well.

b. I have made a mistake - and this is good because I can learn from it
I have made a mistake and I know what I need to do next to learn from it
I find this work hard but I am working hard to understand it

c. This work is awesome - I'm on the right track to being the best that I can.
This is work I didn't think I could do before, and I have worked hard to get here.
I am good at what I am doing now and I am enjoying using my new skills

I really think it is very important we ask children about their attitudes to mistakes : 
I am happy when I make a mistake
I won't be told off if I make a mistake. 
My teacher helps me know what to do next if I make a mistake
I like to help my friends if they make a mistake and I know how to do it.

There are other things in the growth mindset that look at how children approach problems ("This is too hard"; "I can't do French"; "I'll never be as good as her"; "I can't get any better at this"; "I give up") that might be measurable. I am hoping they are, to some extent, captured in the measures above (so for instance, the measure of 'awesomess' is a personal one, and reflects, to me, the extent to which the teacher knows the child and what constitutes challenge and success for them)

3. It matters that my child has enjoys a rich variety of experiences
I'm not sure how I would measure this. How about something like "Number of things my child does that are led by a specialist who is not their usual teacher."

Sex registers and pathology testing

I'm off to London to talk about pathology. On the way I have been listening to the latest Freakeconomics podcast on the economic cost of sex offending. It's big, and lifelong. Society exacts a high price, in a way that is unique amongst all offences. One of the biggest costs is associated with sex registers, which effectively proscribe offenders from even attempting to live a normal life. But this may be the price society exacts for a crime that is seen as most heinous.

What I find interesting, though, is the effect of registers on offending rates. Zero. I don't think this is very surprising. And perhaps it's also not surprising that registers have a wider effect on society. So house prices fall by 4% if you live within half a mile of a registered sex offender in the US.  But then there is the fear they engender. It suddenly becomes a lot easier to imagine your child becoming a victim. And of course it is fear of crime, rather than probability of being a victim of crime, that is the biggest problem, especially for those of us with enough time and resource to be able to search registers.

So the link with pathology? We have created an industry in monitoring of chronic disease which is supposed to make people feel safe, and cared for, but which has actually done the opposite. It has made people live in fear of deviation from the median, and encouraged treatments and health behaviours that lack evidence of actual benefit (as would be defined by the citizen); chasing arbitrary targets that are, at best, a step removed from the true purpose of what we're trying to achieve.

My response to this social disease of iatrogenic harm? I see it as my responsibility, as a pathologist with some degree of influence, to ensure that we act as stewards of pastoral care - only delivering testing when it makes people better. Not using testing to create layers of anxiety. The link here with crime? As a citizen, I see the main role of law enforcement agencies is to make me feel safe. This may involve tackling the causes of crime, but this can only be a part of it. Sex registers most definitely take you away from this purpose - even if they worked (they don't) they make you feel unsafe. The role of health care is similarly not to deliver a long life - it's to make me, as a citizen, feel cared for. We need to start remembering that.

Cognitive dissonance, and turning evidence into behaviour change in antibiotic stewardship

I was walking down a corridor at the hospital today and bumped into one of the urology consultants. He thanked me for some advice I'd given him last week for a patient with a prosthetic valve undergoing a urological procedure. He had thought that prophylaxis wasn't indicated (we had talked about this on a previous occasion, and he knew I'd said quite firmly that it was or wasn't indicated - he just couldn't remember which!). However, his colleague was adamant the patient should be given an antibiotic. So I had reminded him about the NICE guidance which essentially says that there is no evidence for it, and does not recommend it. The trouble with this advice is that it appears rather sterile (if you forgive the pun) in relation to the thought that you might give the patient in front of you a potentially fatal disease (endocarditis). It is especially hard to stop doing something that you have successfully being doing all your working life ie. not giving patients endocarditis, which you have correlated with giving them a pre-procedure antibiotic. So this sets up some cognitive dissonance - your brain is trying to hold two competing views, one in which antibiotics are good (and which chimes with everything you have previously said and done) and one in which antibiotics are bad (which implies that you have been wrong for the last 20 years). It is then a natural reaction to try to dismiss the thing that says you were wrong. We can do this in many ways, from attacking the basis of the evidence, to just forgetting about it. This is why rational cases for behaviour change rarely work. So we need to find ways to address this.

And this is where the conversation became more interesting. He went on to say that the thing that made him remember the 'right' answer, and feel confident that it was OK to withhold antibiotics, was me saying that everyone is bacteraemic whenever they brush their teeth. So if you are going to give antibiotics for this procedure then you should probably consider giving them everytime you brush your teeth. This information allowed him to create an alternative narrative that had equal mental validity with his prior experience. My advice could now sit comfortable in his mental model of the world.

I had a similar experience today when reviewing the latest NICE guidance on the relative risks of different antibiotics for causing C difficile. Not unexpectedly, 3rd generation cephalosporins are high risk. I was pleased to see carbapenems as quite high risk (this is what I wanted to hear). I was also pleased that first generation cephalosporins are low risk, while co-amoxiclav is high risk (we somewhat controversially recommend cefalexin as first line oral option for pyelonephritis in the community). So that was all good. But then trimethoprim came in at high risk. Not what I was expecting, and not what I really wanted to see as it starts to challenge the order of antibiotics we recommend for many infections. My response? I have ignored it. Well, not quite, but I know that I don't believe it. The only way I would believe it is to be taken to the cases of patients who had a clear diagnosis of C diff, and then to be shown the offending trimethoprim prescription. And then for this process to continue until basically my mental model collapsed and I had to rebuild a new truth.

And here we see two powerful ways of tackling dissonance. One is to provide a story which has sufficient power to immediately override prior assumptions. This can be a new piece of evidence, or it could be a single highly emotional patient history. The other way is to take people to the data, and show them it until they accept its validity and their defences collapse. But they have to do this for themselves - meta-analyses will never work.

So in that spirit, I have started adding some statements to some revised UTI guidelines we are writing. This is also bearing in mind the comments of Alison Holmes at the recent ECCMID conference, that we need to talk much more about general principles of stewardship, and worry much less about specifics. The idea is to try to find things that may have the power to immediately shift people's view of the world. This is normative change. Here are some starters - some are general things, some are specific to our local guidelines. I would love to hear some feedback on these, and please feel free to contribute more.

Single doses of antibiotics are often effective

A single dose of any antibiotic is an effective treatment for UTI in most patients. Therapeutic concentrations will be reached for at least 12-24 hours. This is sufficient to achieve cure in over two thirds of patients.

This has been shown for acute cystitis using the following agents:

Amoxicillin     Harbord RB et al (1981) BMJ 283, 1301-2

Septrin             Gossius G (1984) Scand J Infect Dis 16, 373

Quinolones      Saginur R et al. (1992) Arch Intern Med152 1233-7
Tetracycline    Rosenstock J et al (1985) Antimicrob Agents Chemother. 27 652-4

Nitrofurantoin  Gossius G (1984) Curr Ther Res 35, 925-3

Cefaclor          Greenberg RN (1981) Am J Med 71, 841-5

 A single dose of an antibiotic, initiated by the patient when first symptomatic, is effective in recurrent UTI

                                   Wong ES (1985) Ann Intern Med 102, 302-7

UTI symptoms may resolve spontaneously

Up to 50% of women with UTI symptoms recover spontaneously within a week

                                    Mody L (2014) JAMA 311, 844-54

What do others do when trying to diagnose infection in elderly patients with vague symptoms?

A negative dipstick (no nitrites or pyuria) effectively rules out infection in elderly women

                                    Mody L (2014) JAMA 311, 844-54

It is reasonable to observe elderly patients with non-specific symptoms, while correcting hydration and reviewing medication. If, after 24 hours, an infection remains possible, then a dipstick may help in deciding whether to send an MSU, and this result may then guide treatment.

                                    Mody L (2014) JAMA 311, 844-54

 

What is wrong with using dipsticks in catheterised patients?

Dipsticks are completely pointless in catheterised patients.  Even with the best catheter care, 1 in 20 catheters will become colonised with bacteria every day. Long term catheters are almost all colonised with bacteria. Culture is only useful in detecting resistant bacteria, not in making the diagnosis.

Breitenbucher RB (1984) Arch Intern Med144 1585-8

What are the best antibiotics to treat UTI?

 

It is not necessary to cover enterococci in empirical UTI treatment protocols. Cephalosporins and quinolones do not treat enterococci, but are well researched options to treat pyelonephritis as single agents. Gentamicin has been shown to be a good single agent option to treat pyelonephritis

Wie SH (2014) Clin Microb Infect 20, 1211-8

Cefalexin is an effective treatment for UTI in North Devon and is relatively low risk for causing C. difficile. Sensitivity data shows approximately 9 out of 10 UTIs in North Devon. It is not associated with C difficile (unlike 2^nd and 3rd generation cephalosporins, co-amoxiclav or ciprofloxacin)
Clostridium difficile infection: risk with broad-spectrum antibiotics. NICE 2015

What are the downsides of prescribing abx?

Antibiotic resistance is a predictable and very common adverse drug reaction.

Resistant pathogenic bacteria can be detected in one third of patients after antibiotic treatment in hospital.

Gorska et al (2015) ECCMID O001 oral session

Your normal flora might be worth looking after. They may prevent more serious infection :Mice challenged with S. aureus a week before being given influenza are MORE like to survive

Guery et al (2015) ECCMID O001 oral session

Your normal flora might be worth looking after, particularly in children. They may promote a more normal inflammatory response to allergens in the lung, perhaps reducing the risk of asthma. Guery et al (2015) ECCMID O001 oral session

Your normal flora might be worth looking after. Abnormal bacteria in the gut have been associated with many diseases, from obesity to Crohns disease.  Antibiotic treatment induces profound effects in metabolism. Perez-Cobas (2013) Gut 62, 1591

Every dose of antibiotic is a role of the dice - there is a chance that beneficial bacteria may be lost; and harmful bacteria may be gained. The effects of ciprofloxacin are unpredictable, and may sometimes be profound and long lasting, and of unknown physiological relevance Dethlefeson (2011) PNAS108, 4554

How not to harm patients (and control antibiotic use while you're about it)

So I am often asked, as a microbiologist, what I would do if it were me, or my kids, with a sore throat/sinusitis/cough and so on. People seem surprised when I say I would have some paracetamol (maybe with a little whisky and lemon obviously). As though I know that antibiotics are really what's needed, for an individual patient, but that I put public health concerns above this when advising others. Taking this approach, as a doctor I would have to weigh up the benefits of giving an antibiotic (24 hours less symptoms perhaps) but then try to factor in some professional responsibility to 'do the right thing', even if that is in direct conflict with what the patient might want.

But of course a patient wants more than just to get better. They also don't want to be exposed to potential harm. And antibiotic use is not benign. Data presented at ECCMID shows that there are high rates of colonisation with resistant organisms after antibiotic treatment. Clinically relevant? Who knows... But as a patient I might like to know that it might happen. People know that MRSA is not a good thing to have on your skin. And of course there are myriad other risks. From drug reactions to irreversibly altered gut flora (with who knows what consequences).

So looked at this way, over prescribing is not patient centred medicine triumphing over the paternalism of population health. Rather it is a complete failure on behalf of the medical profession to properly consent patients for the things we do to them. So let's start sharing our uncertainties with patients in more honest and open ways.

I was thinking of an analogy. You are driving from A to B. You could do so very fast, breaking the law, increasing the chance of death to you and others; or you could do so more sedately, arriving a bit later, but safely. We might normally do the second, but in some situations, say if time is tight, we might do the first. To make that choice requires 'consent' by considering all consequences, both short and long term, and weighing them up. The answer we get to may not always be rational to others, but perhaps by focusing on rationality we lose the argument? So perhaps the answer to problems of antibiotic stewardship is purely designing ways of sharing risks and benefits with patients and then letting them make the call with us as their impartial advisors.

Designing pathology services through studying demand

So I'm here at ECCMID2015 in lovely Copenhagen. It is clear that the predicted shift from culture to molecular is gaining pace. This will have a major impact on how we organise our laboratories and support clinical medicine. Many people see this as the death knell for local services. I will argue the contrary. For the first time, we have the tools in microbiology (beyond simple microscopy) to deliver results in a time frame that impacts on empirical decisions. In order to work, these tools need to be as near to the decision point as possible, as inevitably transport and other logistical issues will come to dominate the time taken to get a result. We will move from batch processing, to random access or point of care testing. These are things that local services can deliver, but that centralised reference laboratories cannot provide. The irony may be that it is reference labs that will remain the bastion of culture based methods (and perhaps non time critical molecular tests, such as viral load).

So that is all good. But in order to do this we need to change our thinking. We cannot replicate what we do with culture and just do it faster. We need to reconsider the questions we are asking and think about how the results we produce inform action. Just because you can do a test does not mean that you should. We heard today about how highly accurate molecular tests for tuberculosis actually perform poorly in low probability settings. So without considering exactly what test results mean, when applied to a specific setting, we run a real risk of doing more harm than good. And the mystique of molecular makes the risk of blind acceptance of results even greater. I will suggest that we need to go back to studying demand, and by that I mean asking what questions a patient would want to ask, and thinking about how we can answer them. So the question is not 'how can molecular do what I now do faster/better?' Rather it is, 'what clinical decisions can I now support using molecular?'.

And even more importantly, we need to be careful that we don't substitute good clinical assessment for the false security of a test result. Test results can only ever be interpreted in the context of the prior probability that flows from the extraction of clinically relevant information. We need to find ways that help us to resist the siren call of false reassurance, and back our clinical judgement when it is appropriate to do so.

The other concern I have is that small laboratories lack the skills with which to appraise these new technologies. It is easy to be bamboozled by reps promising sensitivities and specificities in excess of 99%, with business cases ready to pull from the shelf. What we need are experts who have a deep understanding of the emerging platforms, with attendant risks and benefits, and perhaps more importantly how they can be fitted together into a coherent package. We need advice on optimum staffing to run these services.

But these are certainly exciting times to be an infection specialist.